March 2016 Br J Cardiol 2016;23:21–6 doi:10.5837/bjc.2016.009
Mamta H Buch
Introduction Dr Mamta Buch, University Hospital of South Manchester NHS Foundation Trust Mitral regurgitation (MR) is increasingly prevalent in developed countries and represents a significant cause of morbidity and mortality. It affects 24% of adults with valvular heart disease and is present in 7% of the population over the age of 75 years.1,2 Significant MR is a complex condition and, left untreated, it leads to slow progressive deterioration. Up to 50% of patients with criteria for surgical intervention are not referred for surgery, largely due to advanced age, significant comorbidities and the presence of left ventricular (LV) dysfunctio
May 2008 Br J Cardiol 2008;15:123–30
Terry McCormack
ENHANCE controversy dominates meeting The controversial ENHANCE (Ezetimibe and Simvastatin in Hypercholesterolaemia Enhances Atherosclerosis Regression) trial of ezetimibe dominated the ACC meeting, with a special session held to discuss the results, which were simultaneously published in the New England Journal of Medicine. The 720-patient trial showed no benefit of ezetimibe when added to simvastatin 80 mg in slowing the progression of atherosclerosis in the carotid artery (as measured by intima media thickness (IMT) in patients with familial hypercholesterolemia (FH), despite the fact that there were significantly greater reductions in lo
January 2004 Br J Cardiol 2004;11:42-9
Joanna Chikwe, Axel Walther, John Pepper
No content available
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits